New combo therapy aims to boost immune attack on hard-to-treat cancers

NCT ID NCT02862275

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard treatments. The goal is to see if the drug can help the infused cells work better against the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM METASTATIC MALIGNANT SOLID NEOPLASM UNRESECTABLE MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342, United States
Emory University Hospital Midtown

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Moffitt Cancer Center-International Plaza

Tampa, Florida, 33607, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
University Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.